際際滷shows by User: gmmyles / http://www.slideshare.net/images/logo.gif 際際滷shows by User: gmmyles / Wed, 24 Jun 2020 22:26:20 GMT 際際滷Share feed for 際際滷shows by User: gmmyles 2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 /slideshow/2020-0128-uwlsaplbiotechdisclosure-under-35usc112/236170240 2020-01-28uwlsaplbiotechdisclosureunder35usc112-200624222620
This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries]]>
This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries]]> Wed, 24 Jun 2020 22:26:20 GMT /slideshow/2020-0128-uwlsaplbiotechdisclosure-under-35usc112/236170240 gmmyles@slideshare.net(gmmyles) 2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 gmmyles This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2020-01-28uwlsaplbiotechdisclosureunder35usc112-200624222620-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112 from Gary M. Myles, Ph.D.
]]> 68 0 https://cdn.slidesharecdn.com/ss_thumbnails/2020-01-28uwlsaplbiotechdisclosureunder35usc112-200624222620-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curiae in Support of Petitioner /slideshow/commil-v-cisco-brief-of-biotechnology-industry-organization-as-amicus-curiae-in-support-of-petitioner/77934433 bioamicusbrief-170716190457
Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896)]]>
Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896)]]> Sun, 16 Jul 2017 19:04:57 GMT /slideshow/commil-v-cisco-brief-of-biotechnology-industry-organization-as-amicus-curiae-in-support-of-petitioner/77934433 gmmyles@slideshare.net(gmmyles) Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curiae in Support of Petitioner gmmyles Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bioamicusbrief-170716190457-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896)
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curiae in Support of Petitioner from Gary M. Myles, Ph.D.
]]> 97 4 https://cdn.slidesharecdn.com/ss_thumbnails/bioamicusbrief-170716190457-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Myriad Decision May Invalidate Many Patents /slideshow/myriad-decision-may-invalidate-many-patents/77934255 singhetal-170716185557
The Court found that separating the DNA of a gene from its surrounding genetic material, even though time consuming and valuable, is not an invention.]]>
The Court found that separating the DNA of a gene from its surrounding genetic material, even though time consuming and valuable, is not an invention.]]> Sun, 16 Jul 2017 18:55:56 GMT /slideshow/myriad-decision-may-invalidate-many-patents/77934255 gmmyles@slideshare.net(gmmyles) Myriad Decision May Invalidate Many Patents gmmyles The Court found that separating the DNA of a gene from its surrounding genetic material, even though time consuming and valuable, is not an invention. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/singhetal-170716185557-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The Court found that separating the DNA of a gene from its surrounding genetic material, even though time consuming and valuable, is not an invention.
Myriad Decision May Invalidate Many Patents from Gary M. Myles, Ph.D.
]]> 55 4 https://cdn.slidesharecdn.com/ss_thumbnails/singhetal-170716185557-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner /slideshow/commil-v-ciscobrief-of-biotechnology-industry-organization-bio-as-amicus-curiae-in-support-of-petitioner/72375744 bioamics-170220183151
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner]]>
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner]]> Mon, 20 Feb 2017 18:31:51 GMT /slideshow/commil-v-ciscobrief-of-biotechnology-industry-organization-bio-as-amicus-curiae-in-support-of-petitioner/72375744 gmmyles@slideshare.net(gmmyles) COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner gmmyles COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bioamics-170220183151-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner from Gary M. Myles, Ph.D.
]]> 158 6 https://cdn.slidesharecdn.com/ss_thumbnails/bioamics-170220183151-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2017 02-15 uwls-apl_biotech 101 /slideshow/2017-0215-uwlsaplbiotech-101/72339781 2017-02-15uwlsaplbiotech101-170219231006
Biotechnology Patents: Utility and eligibility requirements under 35 USC 101. This presentation follows the historical development of the utility requirement from the early 19th century case Lowell v. Lewis (MA 1817), the origin of the specific, substantial, and credible standard for a patent disclosure from Brenner v. Manson (SCOTUS 1966), and the modern application of the Brenner standard for biotechnology patents in In re Fisher (Fed. Cir. 2005). Biotechnology eligibility requirements are discussed from the early Supreme Court case Funk Brothers v. Kalo, the seminal biotechnology Supreme Court case Diamond v. Chakrabarty (SCOTUS 1980) where the court holds that statutory subject matter includes "anything under the sun that is made by man," through the recent Supreme Court decision in Myriad v. ACLU (SCOTUS 2013) where the court held that diagnostic method claims and nucleic acid claims that read on products of nature are patent inelibible. Practice tips are provided to ensure that patent claims avoid the exceptions of 35 USC 101 and withstand scrutiny during litigation and business transactions, such as licensing.]]>
Biotechnology Patents: Utility and eligibility requirements under 35 USC 101. This presentation follows the historical development of the utility requirement from the early 19th century case Lowell v. Lewis (MA 1817), the origin of the specific, substantial, and credible standard for a patent disclosure from Brenner v. Manson (SCOTUS 1966), and the modern application of the Brenner standard for biotechnology patents in In re Fisher (Fed. Cir. 2005). Biotechnology eligibility requirements are discussed from the early Supreme Court case Funk Brothers v. Kalo, the seminal biotechnology Supreme Court case Diamond v. Chakrabarty (SCOTUS 1980) where the court holds that statutory subject matter includes "anything under the sun that is made by man," through the recent Supreme Court decision in Myriad v. ACLU (SCOTUS 2013) where the court held that diagnostic method claims and nucleic acid claims that read on products of nature are patent inelibible. Practice tips are provided to ensure that patent claims avoid the exceptions of 35 USC 101 and withstand scrutiny during litigation and business transactions, such as licensing.]]> Sun, 19 Feb 2017 23:10:06 GMT /slideshow/2017-0215-uwlsaplbiotech-101/72339781 gmmyles@slideshare.net(gmmyles) 2017 02-15 uwls-apl_biotech 101 gmmyles Biotechnology Patents: Utility and eligibility requirements under 35 USC 101. This presentation follows the historical development of the utility requirement from the early 19th century case Lowell v. Lewis (MA 1817), the origin of the specific, substantial, and credible standard for a patent disclosure from Brenner v. Manson (SCOTUS 1966), and the modern application of the Brenner standard for biotechnology patents in In re Fisher (Fed. Cir. 2005). Biotechnology eligibility requirements are discussed from the early Supreme Court case Funk Brothers v. Kalo, the seminal biotechnology Supreme Court case Diamond v. Chakrabarty (SCOTUS 1980) where the court holds that statutory subject matter includes "anything under the sun that is made by man," through the recent Supreme Court decision in Myriad v. ACLU (SCOTUS 2013) where the court held that diagnostic method claims and nucleic acid claims that read on products of nature are patent inelibible. Practice tips are provided to ensure that patent claims avoid the exceptions of 35 USC 101 and withstand scrutiny during litigation and business transactions, such as licensing. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2017-02-15uwlsaplbiotech101-170219231006-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Biotechnology Patents: Utility and eligibility requirements under 35 USC 101. This presentation follows the historical development of the utility requirement from the early 19th century case Lowell v. Lewis (MA 1817), the origin of the specific, substantial, and credible standard for a patent disclosure from Brenner v. Manson (SCOTUS 1966), and the modern application of the Brenner standard for biotechnology patents in In re Fisher (Fed. Cir. 2005). Biotechnology eligibility requirements are discussed from the early Supreme Court case Funk Brothers v. Kalo, the seminal biotechnology Supreme Court case Diamond v. Chakrabarty (SCOTUS 1980) where the court holds that statutory subject matter includes &quot;anything under the sun that is made by man,&quot; through the recent Supreme Court decision in Myriad v. ACLU (SCOTUS 2013) where the court held that diagnostic method claims and nucleic acid claims that read on products of nature are patent inelibible. Practice tips are provided to ensure that patent claims avoid the exceptions of 35 USC 101 and withstand scrutiny during litigation and business transactions, such as licensing.
2017 02-15 uwls-apl_biotech 101 from Gary M. Myles, Ph.D.
]]> 214 5 https://cdn.slidesharecdn.com/ss_thumbnails/2017-02-15uwlsaplbiotech101-170219231006-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2017 01-25 uwls-apl_biotech 112 /slideshow/2017-0125-uwlsaplbiotech-112/72339445 2017-01-25uwlsaplbiotech112-170219225230
Biotechnology Patents: Disclosure Requirements under 35 USC 112. Discusses case law development of the enablement and written description requirements from In re Wright (Fed. Cir. 1993) through Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010), including the origin of the "super enablement" requirement in Regents of the University of California v. Eli Lilly (Fed. Cir. 1997), the thought provoking dissent by Chief Judge Rader in Enzo Biochem v. Gen-Probe (Fed. Cir. 2002), the paradoxical "nascent technology" holding in Chiron v. Genentech (Fed. Cir. 2004), and the risks of relying on functional claim language from Rochester v. Searle (Fed. Cir. 2004). Practice tips are provided for avoiding the pitfalls in patent and claim drafting in view of these seminal cases.]]>
Biotechnology Patents: Disclosure Requirements under 35 USC 112. Discusses case law development of the enablement and written description requirements from In re Wright (Fed. Cir. 1993) through Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010), including the origin of the "super enablement" requirement in Regents of the University of California v. Eli Lilly (Fed. Cir. 1997), the thought provoking dissent by Chief Judge Rader in Enzo Biochem v. Gen-Probe (Fed. Cir. 2002), the paradoxical "nascent technology" holding in Chiron v. Genentech (Fed. Cir. 2004), and the risks of relying on functional claim language from Rochester v. Searle (Fed. Cir. 2004). Practice tips are provided for avoiding the pitfalls in patent and claim drafting in view of these seminal cases.]]> Sun, 19 Feb 2017 22:52:30 GMT /slideshow/2017-0125-uwlsaplbiotech-112/72339445 gmmyles@slideshare.net(gmmyles) 2017 01-25 uwls-apl_biotech 112 gmmyles Biotechnology Patents: Disclosure Requirements under 35 USC 112. Discusses case law development of the enablement and written description requirements from In re Wright (Fed. Cir. 1993) through Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010), including the origin of the "super enablement" requirement in Regents of the University of California v. Eli Lilly (Fed. Cir. 1997), the thought provoking dissent by Chief Judge Rader in Enzo Biochem v. Gen-Probe (Fed. Cir. 2002), the paradoxical "nascent technology" holding in Chiron v. Genentech (Fed. Cir. 2004), and the risks of relying on functional claim language from Rochester v. Searle (Fed. Cir. 2004). Practice tips are provided for avoiding the pitfalls in patent and claim drafting in view of these seminal cases. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2017-01-25uwlsaplbiotech112-170219225230-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Biotechnology Patents: Disclosure Requirements under 35 USC 112. Discusses case law development of the enablement and written description requirements from In re Wright (Fed. Cir. 1993) through Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010), including the origin of the &quot;super enablement&quot; requirement in Regents of the University of California v. Eli Lilly (Fed. Cir. 1997), the thought provoking dissent by Chief Judge Rader in Enzo Biochem v. Gen-Probe (Fed. Cir. 2002), the paradoxical &quot;nascent technology&quot; holding in Chiron v. Genentech (Fed. Cir. 2004), and the risks of relying on functional claim language from Rochester v. Searle (Fed. Cir. 2004). Practice tips are provided for avoiding the pitfalls in patent and claim drafting in view of these seminal cases.
2017 01-25 uwls-apl_biotech 112 from Gary M. Myles, Ph.D.
]]> 255 5 https://cdn.slidesharecdn.com/ss_thumbnails/2017-01-25uwlsaplbiotech112-170219225230-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2015-11-4_WSU_Defining a Corporate Structure for a Startup Company /slideshow/2015114wsudefining-a-corporate-structure-for-a-startup-company/71747414 2015-11-4wsucorpstructureformationforstart-ups-170204050244
This presentation discusses the key factors that are important in selecting an appropriate corporate entity for a startup company]]>
This presentation discusses the key factors that are important in selecting an appropriate corporate entity for a startup company]]> Sat, 04 Feb 2017 05:02:44 GMT /slideshow/2015114wsudefining-a-corporate-structure-for-a-startup-company/71747414 gmmyles@slideshare.net(gmmyles) 2015-11-4_WSU_Defining a Corporate Structure for a Startup Company gmmyles This presentation discusses the key factors that are important in selecting an appropriate corporate entity for a startup company <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2015-11-4wsucorpstructureformationforstart-ups-170204050244-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This presentation discusses the key factors that are important in selecting an appropriate corporate entity for a startup company
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company from Gary M. Myles, Ph.D.
]]> 368 5 https://cdn.slidesharecdn.com/ss_thumbnails/2015-11-4wsucorpstructureformationforstart-ups-170204050244-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 2015-11-4_WSU_Corp Structure & Formation for Start-ups /slideshow/2015114wsucorp-structure-formation-for-startups-55350527/55350527 2a4e9767-b680-45dd-813d-90ac0421109f-151120203818-lva1-app6891
]]>
]]> Fri, 20 Nov 2015 20:38:18 GMT /slideshow/2015114wsucorp-structure-formation-for-startups-55350527/55350527 gmmyles@slideshare.net(gmmyles) 2015-11-4_WSU_Corp Structure & Formation for Start-ups gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2a4e9767-b680-45dd-813d-90ac0421109f-151120203818-lva1-app6891-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
2015-11-4_WSU_Corp Structure & Formation for Start-ups from Gary M. Myles, Ph.D.
]]> 926 8 https://cdn.slidesharecdn.com/ss_thumbnails/2a4e9767-b680-45dd-813d-90ac0421109f-151120203818-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Aziz Sancar 2015 Nobel Prize in Chemistry /slideshow/aziz-sancar-2015-nobel-prize-in-chemistry/53678075 azizsancar2015nobelprizeinchemistry-151008055939-lva1-app6892
Gary's Ph.D. adviser, Aziz Sancar, is awarded the Nobel Prize in Chemistry for his work ion nucleotide excision repair.]]>
Gary's Ph.D. adviser, Aziz Sancar, is awarded the Nobel Prize in Chemistry for his work ion nucleotide excision repair.]]> Thu, 08 Oct 2015 05:59:39 GMT /slideshow/aziz-sancar-2015-nobel-prize-in-chemistry/53678075 gmmyles@slideshare.net(gmmyles) Aziz Sancar 2015 Nobel Prize in Chemistry gmmyles Gary's Ph.D. adviser, Aziz Sancar, is awarded the Nobel Prize in Chemistry for his work ion nucleotide excision repair. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/azizsancar2015nobelprizeinchemistry-151008055939-lva1-app6892-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Gary&#39;s Ph.D. adviser, Aziz Sancar, is awarded the Nobel Prize in Chemistry for his work ion nucleotide excision repair.
Aziz Sancar 2015 Nobel Prize in Chemistry from Gary M. Myles, Ph.D.
]]> 504 7 https://cdn.slidesharecdn.com/ss_thumbnails/azizsancar2015nobelprizeinchemistry-151008055939-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 13-896; tsac; Biotechnology Industry Organization /slideshow/13896-tsac-biotechnology-industry-organization/44410495 2c704aba-7489-4861-868f-2cfa4af8681c-150208122248-conversion-gate02
]]>
]]> Sun, 08 Feb 2015 12:22:48 GMT /slideshow/13896-tsac-biotechnology-industry-organization/44410495 gmmyles@slideshare.net(gmmyles) 13-896; tsac; Biotechnology Industry Organization gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2c704aba-7489-4861-868f-2cfa4af8681c-150208122248-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
13-896; tsac; Biotechnology Industry Organization from Gary M. Myles, Ph.D.
]]> 458 3 https://cdn.slidesharecdn.com/ss_thumbnails/2c704aba-7489-4861-868f-2cfa4af8681c-150208122248-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Genetics (US Supreme Court 2013) /slideshow/mg-whitesheet-on-molecular-pathology-v-myriad-genetics-scotus-2013-23874036/23874036 mgwhitesheetonmolecularpathologyv-myriadgeneticsscotus2013-130703145502-phpapp02
This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.]]>
This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.]]> Wed, 03 Jul 2013 14:55:02 GMT /slideshow/mg-whitesheet-on-molecular-pathology-v-myriad-genetics-scotus-2013-23874036/23874036 gmmyles@slideshare.net(gmmyles) Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Genetics (US Supreme Court 2013) gmmyles This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/mgwhitesheetonmolecularpathologyv-myriadgeneticsscotus2013-130703145502-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This Merchant &amp; Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Genetics (US Supreme Court 2013) from Gary M. Myles, Ph.D.
]]> 651 5 https://cdn.slidesharecdn.com/ss_thumbnails/mgwhitesheetonmolecularpathologyv-myriadgeneticsscotus2013-130703145502-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds document White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Protecting the Inventions of Start-ups /slideshow/mg-icogenex-protecting-inventions-of-startups-27-jun13/23872987 mgicogenex-protectinginventionsofstart-ups-27jun13-130703142656-phpapp02
This presentation addresses the why, what, and how to protect inventions from the vantage point of the early-stage, pre-financing, start-up company that is interested in patenting its inventions and developing an intellectual property portfolio that maximizes the company's valuation and sets it up for success during the intellectual property due diligence that accompanies financing rounds, corporate partnerships, commercialization, and merger and acquisition.]]>
This presentation addresses the why, what, and how to protect inventions from the vantage point of the early-stage, pre-financing, start-up company that is interested in patenting its inventions and developing an intellectual property portfolio that maximizes the company's valuation and sets it up for success during the intellectual property due diligence that accompanies financing rounds, corporate partnerships, commercialization, and merger and acquisition.]]> Wed, 03 Jul 2013 14:26:56 GMT /slideshow/mg-icogenex-protecting-inventions-of-startups-27-jun13/23872987 gmmyles@slideshare.net(gmmyles) Protecting the Inventions of Start-ups gmmyles This presentation addresses the why, what, and how to protect inventions from the vantage point of the early-stage, pre-financing, start-up company that is interested in patenting its inventions and developing an intellectual property portfolio that maximizes the company's valuation and sets it up for success during the intellectual property due diligence that accompanies financing rounds, corporate partnerships, commercialization, and merger and acquisition. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/mgicogenex-protectinginventionsofstart-ups-27jun13-130703142656-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This presentation addresses the why, what, and how to protect inventions from the vantage point of the early-stage, pre-financing, start-up company that is interested in patenting its inventions and developing an intellectual property portfolio that maximizes the company&#39;s valuation and sets it up for success during the intellectual property due diligence that accompanies financing rounds, corporate partnerships, commercialization, and merger and acquisition.
Protecting the Inventions of Start-ups from Gary M. Myles, Ph.D.
]]> 608 6 https://cdn.slidesharecdn.com/ss_thumbnails/mgicogenex-protectinginventionsofstart-ups-27jun13-130703142656-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Preparing for a Financial Audit & Corporate Due Diligence /slideshow/preparing-for-a-financial-audit-corporate-due-diligence/17380541 biotechseminar-preparingforafinancialauditcorporateduediligence-130319154334-phpapp02
]]>
]]> Tue, 19 Mar 2013 15:43:33 GMT /slideshow/preparing-for-a-financial-audit-corporate-due-diligence/17380541 gmmyles@slideshare.net(gmmyles) Preparing for a Financial Audit & Corporate Due Diligence gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/biotechseminar-preparingforafinancialauditcorporateduediligence-130319154334-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Preparing for a Financial Audit & Corporate Due Diligence from Gary M. Myles, Ph.D.
]]> 1680 5 https://cdn.slidesharecdn.com/ss_thumbnails/biotechseminar-preparingforafinancialauditcorporateduediligence-130319154334-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutical Patent Attorney -- Resume and Curriculum Vitae /slideshow/gary-myles-resume-02-aug12/13844605 garymylesresume02aug12-13439448955743-phpapp01-120802170301-phpapp01
This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.]]>
This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.]]> Thu, 02 Aug 2012 17:01:40 GMT /slideshow/gary-myles-resume-02-aug12/13844605 gmmyles@slideshare.net(gmmyles) Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutical Patent Attorney -- Resume and Curriculum Vitae gmmyles This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/garymylesresume02aug12-13439448955743-phpapp01-120802170301-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutical Patent Attorney -- Resume and Curriculum Vitae from Gary M. Myles, Ph.D.
]]> 2221 11 https://cdn.slidesharecdn.com/ss_thumbnails/garymylesresume02aug12-13439448955743-phpapp01-120802170301-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds document White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 CASRIP 2012 -- Patenting of Human DNA and Embryos /slideshow/casrip-2012-patenting-of-human-dna-embryos-and-organs-28-jul12-27-jul12/13804165 casrip2012patentingofhumandnaembryosandorgans28jul1227jul12-13436670568358-phpapp01-120730115224-phpapp01
]]>
]]> Mon, 30 Jul 2012 11:51:15 GMT /slideshow/casrip-2012-patenting-of-human-dna-embryos-and-organs-28-jul12-27-jul12/13804165 gmmyles@slideshare.net(gmmyles) CASRIP 2012 -- Patenting of Human DNA and Embryos gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/casrip2012patentingofhumandnaembryosandorgans28jul1227jul12-13436670568358-phpapp01-120730115224-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
CASRIP 2012 -- Patenting of Human DNA and Embryos from Gary M. Myles, Ph.D.
]]> 376 5 https://cdn.slidesharecdn.com/ss_thumbnails/casrip2012patentingofhumandnaembryosandorgans28jul1227jul12-13436670568358-phpapp01-120730115224-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 America Invents Act: Recent Changes to US Patent Law and Practice /slideshow/america-invents-act-recent-changes-to-us-patent-law-and-practice-06-feb12-11503236/11503236 americainventsactrecentchangestouspatentlawandpractice06feb12-13288180369158-phpapp02-120209140829-phpapp02
]]>
]]> Thu, 09 Feb 2012 14:07:19 GMT /slideshow/america-invents-act-recent-changes-to-us-patent-law-and-practice-06-feb12-11503236/11503236 gmmyles@slideshare.net(gmmyles) America Invents Act: Recent Changes to US Patent Law and Practice gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/americainventsactrecentchangestouspatentlawandpractice06feb12-13288180369158-phpapp02-120209140829-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
America Invents Act: Recent Changes to US Patent Law and Practice from Gary M. Myles, Ph.D.
]]> 1096 11 https://cdn.slidesharecdn.com/ss_thumbnails/americainventsactrecentchangestouspatentlawandpractice06feb12-13288180369158-phpapp02-120209140829-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Biotechnology Patent Eligibility /slideshow/biotechnology-patent-eligibility-u-of-washington-01-feb12-11503227/11503227 biotechnologypatenteligibilityuofwashington01feb12-13288179906407-phpapp01-120209140753-phpapp01
This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain.]]>
This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain.]]> Thu, 09 Feb 2012 14:06:33 GMT /slideshow/biotechnology-patent-eligibility-u-of-washington-01-feb12-11503227/11503227 gmmyles@slideshare.net(gmmyles) Biotechnology Patent Eligibility gmmyles This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/biotechnologypatenteligibilityuofwashington01feb12-13288179906407-phpapp01-120209140753-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain.
Biotechnology Patent Eligibility from Gary M. Myles, Ph.D.
]]> 916 8 https://cdn.slidesharecdn.com/ss_thumbnails/biotechnologypatenteligibilityuofwashington01feb12-13288179906407-phpapp01-120209140753-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Les Aia Stanford And Effect Of Valuation 09 Nov11 /slideshow/les-aia-stanford-and-effect-of-valuation-09-nov11-10437571/10437571 lesaiastanfordandeffectofvaluation09nov11-13228510848218-phpapp02-111202133407-phpapp02
]]>
]]> Fri, 02 Dec 2011 12:38:11 GMT /slideshow/les-aia-stanford-and-effect-of-valuation-09-nov11-10437571/10437571 gmmyles@slideshare.net(gmmyles) Les Aia Stanford And Effect Of Valuation 09 Nov11 gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/lesaiastanfordandeffectofvaluation09nov11-13228510848218-phpapp02-111202133407-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Les Aia Stanford And Effect Of Valuation 09 Nov11 from Gary M. Myles, Ph.D.
]]> 201 3 https://cdn.slidesharecdn.com/ss_thumbnails/lesaiastanfordandeffectofvaluation09nov11-13228510848218-phpapp02-111202133407-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Patenting In The Biotech Industry 21 Sep10 /slideshow/patenting-in-the-biotech-industry-21-sep10/5317383 patentinginthebiotechindustry21sep10-12857840802949-phpapp02
]]>
]]> Wed, 29 Sep 2010 13:14:48 GMT /slideshow/patenting-in-the-biotech-industry-21-sep10/5317383 gmmyles@slideshare.net(gmmyles) Patenting In The Biotech Industry 21 Sep10 gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/patentinginthebiotechindustry21sep10-12857840802949-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Patenting In The Biotech Industry 21 Sep10 from Gary M. Myles, Ph.D.
]]> 812 7 https://cdn.slidesharecdn.com/ss_thumbnails/patentinginthebiotechindustry21sep10-12857840802949-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds document 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Biotechnology Novelty And Nonobviousness 14 Sep10 /slideshow/biotechnology-novelty-and-nonobviousness-14-sep10/5317210 biotechnologynoveltyandnonobviousness14sep10-12857832280106-phpapp01
]]>
]]> Wed, 29 Sep 2010 13:00:30 GMT /slideshow/biotechnology-novelty-and-nonobviousness-14-sep10/5317210 gmmyles@slideshare.net(gmmyles) Biotechnology Novelty And Nonobviousness 14 Sep10 gmmyles <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/biotechnologynoveltyandnonobviousness14sep10-12857832280106-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Biotechnology Novelty And Nonobviousness 14 Sep10 from Gary M. Myles, Ph.D.
]]> 279 1 https://cdn.slidesharecdn.com/ss_thumbnails/biotechnologynoveltyandnonobviousness14sep10-12857832280106-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-gmmyles-48x48.jpg?cb=1593037512 As a biotechnology patent attorney, Gary drafts and prosecutes patent applications for a broad range of life sciences inventions and develops intellectual property strategies for university, non-profit, start-up, and mid- and large-cap bio/pharma clients in the life sciences and agricultural industries. Gary also formulates freedom-to-operate, non-infringement and invalidity opinions and performs intellectual property due diligence reviews. His areas of technological expertise include molecular and cell biology, biochemistry, virology, cell biology, immunology, nanotechnology, and personalized medicine. Gary's scientific experience includes post-doctoral research on the molecular mecha... www.merchantgould.com/Profile_Myles_Gary.aspx https://cdn.slidesharecdn.com/ss_thumbnails/2020-01-28uwlsaplbiotechdisclosureunder35usc112-200624222620-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/2020-0128-uwlsaplbiotechdisclosure-under-35usc112/236170240 2020 01-28 uwls-apl_bi... https://cdn.slidesharecdn.com/ss_thumbnails/bioamicusbrief-170716190457-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/commil-v-cisco-brief-of-biotechnology-industry-organization-as-amicus-curiae-in-support-of-petitioner/77934433 Commil v. Cisco: Brie... https://cdn.slidesharecdn.com/ss_thumbnails/singhetal-170716185557-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/myriad-decision-may-invalidate-many-patents/77934255 Myriad Decision May In...